A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE

Trial Profile

A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms RETRIEVE
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 08 Aug 2014 Primary endpoint (Objective clinical response rate) has been met, according to a Takeda media release.
    • 08 Aug 2014 Top-line results published in a Takeda media release.
    • 08 Aug 2014 Based on the results of this trial, the US FDA has approved bortezomib for retreatment of adults with multiple myeloma who had previously responded to VELCADE therapy and relapsed, according to a Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top